|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||34.11 - 36.49|
|52 Week Range||31.46 - 107.69|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 07, 2022 - Mar. 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.29|
FRIENDSWOOD, Texas, January 24, 2022--Castle Biosciences will present data highlighting its portfolio of skin cancer tests at Maui Derm for Dermatologists 2022, Jan. 24-28, 2022.
FRIENDSWOOD, Texas, January 13, 2022--Castle announced the publication of clinical performance study data related to DecisionDx®-SCC in Future Oncology.
FRIENDSWOOD, Texas, January 12, 2022--Castle announced the publication of a study in Ocular Oncology and Pathology related to the Company's DecisionDx®-UMSeq 7-gene DNA sequencing panel.